금융 서비스를 넘어서는 블록체인 기회

---

Blockchain Opportunities Beyond Financial Services: Where Distributed Ledgers Create Real Enterprise Value

Distributed ledger technology has matured well past its origins in payments. The most interesting applications now sit in supply chains, identity, intellectual property, and clinical data. Blockchain Opportunities Beyond Financial Services have moved from pilots to production deployments at companies including Maersk, Walmart, De Beers, and Pfizer.

The pattern is consistent. Wherever multiple parties need a shared source of truth, where reconciliation costs are high, or where provenance carries economic value, distributed ledgers compress friction that legacy databases cannot. The opportunity for VPs is not the technology itself. It is identifying which internal workflows carry hidden reconciliation tax.

Supply Chain Provenance Is the First Operational Win

Walmart’s leafy greens traceability program with IBM Food Trust reduced product trace time from days to seconds. De Beers operates Tracr to authenticate diamonds from mine to retail. Maersk and IBM built TradeLens for container documentation before transitioning the model to industry consortia.

The mechanism matters. In multi-tier supply chains, each handoff generates duplicate records across ERP systems, EDI feeds, and manual paperwork. A shared ledger replaces reconciliation with a single immutable record visible to permissioned parties. The savings are not theoretical. They show up in working capital release, faster recall execution, and lower customs friction.

SIS International’s B2B expert interviews with senior supply chain executives across consumer goods, pharmaceuticals, and industrial manufacturing indicate that provenance-led blockchain deployments deliver the strongest return when paired with existing IoT sensor investments. The ledger validates what sensors record. Without that pairing, the data quality problem moves rather than resolves.

Digital Identity Is the Quiet Infrastructure Play

Estonia’s e-Residency program, built on KSI blockchain, allows non-residents to register companies and sign documents remotely. Microsoft’s ION network, anchored to Bitcoin, provides decentralized identifiers under W3C standards. The European Union’s eIDAS 2.0 framework introduces an EU Digital Identity Wallet that relies on verifiable credentials issued through distributed infrastructure.

For enterprise buyers, the relevant application is workforce and supplier identity. Onboarding a new contractor in a regulated industry typically involves redundant KYC checks across procurement, IT, security, and compliance. Verifiable credentials anchored to a ledger let the contractor present cryptographic proofs once and reuse them across counterparties. The cost reduction is meaningful in industries with high contractor turnover.

Intellectual Property and Royalty Tracking Reach Maturity

The music industry has run the longest experiments. ASCAP, SACEM, and PRS for Music have tested shared rights databases on distributed ledgers to resolve metadata mismatches that delay royalty payments. Sony Music Entertainment has filed patents around blockchain-based rights management. In pharmaceuticals and engineering, the equivalent use case is patent licensing and royalty distribution across joint development agreements.

The conventional approach centralizes rights data in a single registry operated by one party. The better alternative, used by leading consortia, distributes the registry while keeping commercial terms private through zero-knowledge proofs. Parties prove entitlement without exposing contract value. That structural choice is what separates pilots that scale from pilots that stall.

Healthcare Data and Clinical Trials Show Concentrated Upside

Pfizer, Amgen, and Sanofi participated in the MediLedger Project to track pharmaceutical serial numbers under DSCSA requirements. The FDA’s pilot programs with IBM, KPMG, Merck, and Walmart established that ledger-based traceability satisfies regulatory intent at lower operating cost than centralized alternatives. Clinical trial integrity is the next frontier, where immutable audit trails of protocol amendments and consent reduce regulatory query volume.

에 따르면 SIS 국제 연구, life sciences executives consistently rank trial data integrity and patient consent management as the highest-value blockchain use cases inside their portfolios, ahead of supply chain serialization. The driver is regulatory leverage. A defensible audit trail compresses FDA and EMA inspection timelines and reduces the likelihood of clinical hold events.

Where the Value Concentrates: A Practitioner’s Filter

Not every workflow benefits from a ledger. The applications that scale share four properties.

Source: SIS International Research

This filter explains why payments adoption proceeded faster in cross-border corridors than in domestic card networks. It also explains why supply chain, identity, IP, and healthcare applications have produced the most durable enterprise deployments.

Architecture Choices That Separate Production from Pilot

The firms running blockchain at scale have settled on a small set of architectural decisions. Permissioned networks (Hyperledger Fabric, R3 Corda, Quorum) dominate enterprise use. Public chain anchoring is reserved for timestamping and identity rooting. Off-chain storage handles large data, with hashes committed on-chain. Smart contracts encode business logic but stop short of regulatory interpretation.

The deployments that fail tend to over-rely on token economics where they are not needed, or under-invest in governance among consortium members. Governance is the harder problem. Technology choices are reversible. Consortium agreements about data rights, fee structures, and exit terms are not.

What Leading Firms Do Differently

SIS International’s competitive intelligence work across technology adoption cycles points to a consistent pattern among firms that capture value early. They run blockchain proofs of concept inside a single business unit with a named P&L owner, attached to a workflow with measurable reconciliation cost. They avoid horizontal “innovation lab” structures that produce demos without deployment.

The second pattern is consortium leadership. Companies that help write the governance rules of an industry ledger capture more value than those that join later. De Beers in diamonds, Maersk in shipping, and Walmart in food traceability all moved early enough to shape standards rather than comply with them.

The Strategic Question for VP-Level Buyers

Blockchain Opportunities Beyond Financial Services are not a technology bet. They are a structural bet on which industry workflows still carry reconciliation tax that distributed ledgers can remove. The diagnostic work is more valuable than the build work. Identifying the right workflow and the right consortium partners determines whether a deployment compounds or stalls.

For Fortune 500 leadership teams, the productive next step is a structured assessment of internal workflows against the four-filter model, paired with competitive intelligence on consortium activity in the relevant vertical. Blockchain Opportunities Beyond Financial Services reward firms that move with evidence, not enthusiasm.

SIS 인터내셔널 소개

SIS 국제 정량적, 정성적, 전략 연구를 제공합니다. 우리는 의사결정을 위한 데이터, 도구, 전략, 보고서 및 통찰력을 제공합니다. 또한 인터뷰, 설문 조사, 포커스 그룹, 기타 시장 조사 방법 및 접근 방식을 수행합니다. 문의하기 다음 시장 조사 프로젝트를 위해.